So-Young International Inc. reports Q1 2026 revenue of RMB 433M, up 46% YoY. Aesthetic center revenue jumps 186% with strong growth outlook.

Key Takeaways

• Total revenue for Q1 2026 reached RMB 433 million, representing a 46% year-over-year increase.
• Revenue from the aesthetic center business soared to RMB 282 million, marking a 186% year-over-year growth.
• The company expanded its footprint to 59 centers, adding 10 new centers since the end of 2025.
• Average revenue per center for mature centers was approximately RMB 7.5 million, reflecting strong operational efficiency.
• The gross margin for the aesthetic center business improved to 27%, highlighting continued operational gains.

Financial Performance

So-Young International Inc. kicked off 2026 with a stellar financial performance, as evidenced by its Q1 results. The company reported total revenue of RMB 433 million, which is an impressive 46% increase from the same quarter last year. This growth was largely driven by its aesthetic center business, which generated RMB 282 million in revenue, soaring 186% year-over-year.

The operational expansion has also been remarkable, with So-Young operating 59 centers across 17 provinces, compared to 49 centers at the end of 2025, representing a net addition of 10 centers. As of March 31, 2026, the company reported 148,000 verified treatment visits and over 325,000 treatments performed, showing a strong demand for its services.

Despite a net loss of RMB 49.2 million, compared to RMB 33.1 million in the prior year period, the company has maintained a strong cash position with RMB 880 million in cash and equivalents. This strategic capital allocation is aimed at fueling further expansion in the aesthetic center business.

Strategic Initiatives

So-Young has effectively positioned itself as a leader in China's medical aesthetics chain market, focusing on operational efficiency and scalability. The management highlighted several strategic initiatives during the earnings call:

• Expansion of Aesthetic Centers: The opening of new centers contributes significantly to revenue growth. The company continues to target major tier 1 cities, where economies of scale are expected to enhance revenue per center.
• Strengthening Supply Chain: Partnerships, such as the collaboration with Jinbu Biopharmaceutical, have been pivotal. This partnership allows for exclusive rights to new products, enhancing So-Young's product offerings, including the successful launch of its Miracle Collagen line.
• Enhanced User Experience: The company has implemented a physician-led consultation policy, ensuring that all new customers receive professional consultations from physicians, which boosts customer trust and service quality.
• Innovative Marketing: So-Young has successfully launched co-branded campaigns with high-profile brands like Disney, significantly improving brand recognition and customer engagement.

Future Outlook

Looking ahead, So-Young is poised for continued growth. Management expects Q2 2026 aesthetic treatment service revenues to range between RMB 307 million and RMB 317 million, indicating a year-over-year growth of 102.6% to 119.5%. This optimistic guidance reflects confidence in their ongoing strategies and market conditions.

The company's emphasis on expanding its core aesthetic center business, optimizing supply chain operations, and enhancing medical delivery capabilities are crucial for maintaining its competitive edge. The management expressed optimism about the broader market potential, forecasting that the medical aesthetics market in China could exceed RMB 600 billion by 2030, positioning So-Young to capture significant market share.

Furthermore, the company is focused on improving its average revenue per user (ARPU) through tailored services for core members and expanding its mid-to-high-end offerings. This strategic approach is expected to drive higher customer lifetime value and solidify So-Young's leadership in the industry.

In conclusion, So-Young International Inc. has demonstrated robust performance in Q1 2026, with strong revenue growth, strategic initiatives aimed at expanding its market footprint, and an optimistic outlook for the future. The company's focus on operational excellence, customer experience, and innovative marketing strategies positions it well for sustained growth in the evolving medical aesthetics landscape.

This analysis is based on public earnings call materials and is not investment advice.